230961-08-7

Basic information

• Product Name: N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine
• Synonyms: N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine;UK 356618;(2R)-N1-[(1S)-2,2-DiMethyl-1-[[[(1R)-1-phenylethyl]aMino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-Methyl[1,1'-biphenyl]-4-yl)propyl]butanediaMide;PF-03890101;(2R)-N1-[(1S)-2,2-Dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]-2-{3-[(3-methyl-4-phenyl)-phenyl]propyl}-(N4-hydroxy)butanediamide
• CAS NO: 230961-08-7
• Molecular Formula: C34H43N3O4
• Molecular Weight: 557.72292
• Product Categories: Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer Compounds;Pharmaceuticals
• Mol File: 230961-08-7.mol

Chemical Properties

• Appearance: white to tan/
• Storage Temp.: Store at -20°C
• Solubility: DMSO: ≥25mg/mL
• CAS DataBase Reference: N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine(230961-08-7)
• EPA Substance Registry System: N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine(230961-08-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 230961-08-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine is used as a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) for its high inhibitory activity (IC50 = 5.9 nM). This makes it a promising candidate for the development of therapeutic agents targeting MMP-3 related diseases and conditions.
Used in Research Applications:
In research settings, this compound is utilized to study the role and regulation of matrix metalloproteases, particularly MMP-3, in various biological processes and disease pathways. Its selectivity over other MMPs (with IC50 values ranging from 73 to 51000 for MMP-13, MMP-9, MMP-2, MMP-14, and MMP-1, respectively) allows for targeted investigations and the development of more specific research tools.
Used in Drug Discovery and Development:
Due to its high potency and selectivity, N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine serves as a valuable lead compound in drug discovery and development programs. It can be further optimized and modified to improve its pharmacokinetic properties, efficacy, and safety profile for potential clinical applications in treating diseases associated with MMP-3 dysregulation.

Upstream product

• 230961-69-0 tert-butyl (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)hex-5-enoate 
• 98-80-6 phenylboronic acid 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 116632-39-4 2-methyl-4-bromoiodobenzene 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 230962-03-5 tert-butyl (3R,5E)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-[(3-methyl-4-phenyl)phenyl]hex-5-enoate 
• 230961-70-3 tert-butyl (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-[(3-methyl-4-phenyl)phenyl]hexanoate 
• 230961-06-5 (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-[(3-methyl-4-phenyl)phenyl]hexanoic acid 
• 179533-97-2 (R)-2-(2-(tert-butoxy)-2-oxoethyl)pent-4-enoic acid 
• 5002-26-6 3-methyl-4-phenylbromobenzene 
• 230961-45-2 N₁-[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]-(2R)-2-{3-[3-methyl-(4-phenyl)phenyl]propyl}-(N₄-3-propenyloxy)butanediamide 

Relevant articles and documents

Matrix metalloprotease inhibitors

Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors

Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1)

Structure-activity relationships are described for a series of succinyl hydroxamic acids 4a-O as potent and selective inhibitors of matrix metalloprotease-3 (stromelysin-1). Optimisation of P1′ and P3′ groups gave compound 4j (MMP-3 IC50 = 5.9 nM) which was >140-fold less potent against MMP-1 (IC50 = 51,000 nM), MMP-2 (IC50 = 1790 nM), MMP-9 (IC50 = 840 nM) and MMP-14 (IC50 = 1900 nM).